Form 8-K - Current report:
SEC Accession No. 0001193125-21-163810
Filing Date
2021-05-17
Accepted
2021-05-17 16:53:10
Documents
17
Period of Report
2021-05-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d178148d8k.htm   iXBRL 8-K 33601
2 EX-1.1 d178148dex11.htm EX-1.1 231281
3 EX-5.1 d178148dex51.htm EX-5.1 10346
4 EX-99.1 d178148dex991.htm EX-99.1 9461
8 GRAPHIC g178148g0515094711658.jpg GRAPHIC 3915
9 GRAPHIC g178148g0515120525861.jpg GRAPHIC 2972
  Complete submission text file 0001193125-21-163810.txt   489840

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA clvs-20210517.xsd EX-101.SCH 3088
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE clvs-20210517_lab.xml EX-101.LAB 18139
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clvs-20210517_pre.xml EX-101.PRE 11420
10 EXTRACTED XBRL INSTANCE DOCUMENT d178148d8k_htm.xml XML 3356
Mailing Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301
Business Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 (303) 625-5000
Clovis Oncology, Inc. (Filer) CIK: 0001466301 (see all company filings)

EIN.: 900475355 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35347 | Film No.: 21931767
SIC: 2834 Pharmaceutical Preparations